These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1158 related items for PubMed ID: 29375205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL.
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML, Oldham S, Boland BB, Will S, Lapointe JM, Guionaud S, Rhodes CJ, Trevaskis JL.
    World J Gastroenterol; 2018 Apr 28; 24(16):1748-1765. PubMed ID: 29713129
    [Abstract] [Full Text] [Related]

  • 10. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K, Xu Y, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, Zhang Y.
    Mol Metab; 2018 Mar 28; 9():131-140. PubMed ID: 29361497
    [Abstract] [Full Text] [Related]

  • 11. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.
    Comeglio P, Cellai I, Mello T, Filippi S, Maneschi E, Corcetto F, Corno C, Sarchielli E, Morelli A, Rapizzi E, Bani D, Guasti D, Vannelli GB, Galli A, Adorini L, Maggi M, Vignozzi L.
    J Endocrinol; 2018 Aug 28; 238(2):107-127. PubMed ID: 29945982
    [Abstract] [Full Text] [Related]

  • 12. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
    Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, Bhasin K, Jones BA, Orlicky DJ, Takahashi S, Dvornikov A, Kleiner DE, Hewitt SM, Adorini L, Kopp JB, Krausz KW, Rosenberg A, McManaman JL, Robertson CE, Ir D, Frank DN, Luo Y, Gonzalez FJ, Gratton E, Levi M.
    J Biol Chem; 2022 Nov 28; 298(11):102530. PubMed ID: 36209823
    [Abstract] [Full Text] [Related]

  • 13. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct 28; 1864(10):1422-1437. PubMed ID: 31325638
    [Abstract] [Full Text] [Related]

  • 14. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX, Wang D, Luo Y, Myakala K, Dobrinskikh E, Rosenberg AZ, Levi J, Kopp JB, Field A, Hill A, Lucia S, Qiu L, Jiang T, Peng Y, Orlicky D, Garcia G, Herman-Edelstein M, D'Agati V, Henriksen K, Adorini L, Pruzanski M, Xie C, Krausz KW, Gonzalez FJ, Ranjit S, Dvornikov A, Gratton E, Levi M.
    J Am Soc Nephrol; 2018 Jan 28; 29(1):118-137. PubMed ID: 29089371
    [Abstract] [Full Text] [Related]

  • 15. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, Chiang JYL.
    J Biol Chem; 2017 Jun 30; 292(26):11055-11069. PubMed ID: 28478385
    [Abstract] [Full Text] [Related]

  • 16. Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice.
    He B, Jiang J, Shi Z, Wu L, Yan J, Chen Z, Luo M, Cui D, Xu S, Yan M, Zhang S, Chen Z.
    Biomed Pharmacother; 2021 Mar 30; 135():111183. PubMed ID: 33401222
    [Abstract] [Full Text] [Related]

  • 17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May 30; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 18. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN, Veidal SS, Rigbolt KT, Tølbøl KS, Roth JD, Jelsing J, Vrang N, Feigh M.
    World J Hepatol; 2016 Jun 08; 8(16):673-84. PubMed ID: 27326314
    [Abstract] [Full Text] [Related]

  • 19. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH, Gillum MP, Vrang N, Jelsing J, Hansen HH, Feigh M, Oró D.
    Am J Physiol Gastrointest Liver Physiol; 2023 May 01; 324(5):G378-G388. PubMed ID: 36852934
    [Abstract] [Full Text] [Related]

  • 20. Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
    Anfuso B, Tiribelli C, Adorini L, Rosso N.
    Sci Rep; 2020 Feb 03; 10(1):1699. PubMed ID: 32015483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.